OBJECTIVE: To investigate highly active antiretroviral therapy (HAART) initiation among pregnant women and the optimum model of service delivery for integrating HAART services into antenatal care. METHODS: We analysed clinic records to reconstruct a cohort of all HIV-infected pregnant women eligible for HAART at four antenatal clinics representing three service delivery models in Cape Town, South Africa. To assess HAART coverage, records of women determined to be eligible for HAART in pregnancy were reviewed at corresponding HIV treatment services. RESULTS: Of 13,208 pregnant women tested for HIV, 26% were HIV-infected and 15% were HAART-eligible based on a CD4 cell count of <or= 200 cells/microl. Among eligible women, 51% initiated HAART before delivery, 27% received another prevention of mother-to-child transmission (PMTCT) intervention and 22% did not receive any antiretroviral intervention before delivery. The proportions of women initiating HAART between the different service delivery models were comparable. The median gestational age at first presentation was 26 weeks, and early gestational age at first presentation was the strongest predictor of being on HAART by delivery. Of the women who did not initiate HAART in pregnancy, 24% started treatment within 2 years postpartum. CONCLUSIONS: In this setting with clear PMTCT and HAART protocols, services failed to prioritize and initiate a high proportion of eligible pregnant women on HAART. The initiation of HAART in pregnancy requires strengthened antenatal and HIV services that target women with advanced stage disease.
OBJECTIVE: To investigate highly active antiretroviral therapy (HAART) initiation among pregnant women and the optimum model of service delivery for integrating HAART services into antenatal care. METHODS: We analysed clinic records to reconstruct a cohort of all HIV-infected pregnant women eligible for HAART at four antenatal clinics representing three service delivery models in Cape Town, South Africa. To assess HAART coverage, records of women determined to be eligible for HAART in pregnancy were reviewed at corresponding HIV treatment services. RESULTS: Of 13,208 pregnant women tested for HIV, 26% were HIV-infected and 15% were HAART-eligible based on a CD4 cell count of <or= 200 cells/microl. Among eligible women, 51% initiated HAART before delivery, 27% received another prevention of mother-to-child transmission (PMTCT) intervention and 22% did not receive any antiretroviral intervention before delivery. The proportions of women initiating HAART between the different service delivery models were comparable. The median gestational age at first presentation was 26 weeks, and early gestational age at first presentation was the strongest predictor of being on HAART by delivery. Of the women who did not initiate HAART in pregnancy, 24% started treatment within 2 years postpartum. CONCLUSIONS: In this setting with clear PMTCT and HAART protocols, services failed to prioritize and initiate a high proportion of eligible pregnant women on HAART. The initiation of HAART in pregnancy requires strengthened antenatal and HIV services that target women with advanced stage disease.
Authors: Katherine C Liu; Jessica Mulindwa; Mark J Giganti; Nande B Putta; Namwinga Chintu; Benjamin H Chi; Jeffrey S A Stringer; Elizabeth M Stringer Journal: J Acquir Immune Defic Syndr Date: 2011-08-15 Impact factor: 3.731
Authors: Irene N Njuguna; Anjuli D Wagner; Lisa M Cranmer; Vincent O Otieno; Judith A Onyango; Daisy J Chebet; Helen M Okinyi; Sarah Benki-Nugent; Elizabeth Maleche-Obimbo; Jennifer A Slyker; Grace C John-Stewart; Dalton C Wamalwa Journal: AIDS Patient Care STDS Date: 2016-03 Impact factor: 5.078
Authors: Janet M Turan; Maricianah Onono; Rachel L Steinfeld; Starley B Shade; Kevin Owuor; Sierra Washington; Elizabeth A Bukusi; Marta L Ackers; Jackson Kioko; Evelyn C Interis; Craig R Cohen Journal: J Acquir Immune Defic Syndr Date: 2015-08-15 Impact factor: 3.731
Authors: Kate Clouse; Audrey Pettifor; Kate Shearer; Mhairi Maskew; Jean Bassett; Bruce Larson; Annelies Van Rie; Ian Sanne; Matthew P Fox Journal: Trop Med Int Health Date: 2013-02-03 Impact factor: 2.622